From: Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
 | No. of patients | HR (95% CI) | P value |
---|---|---|---|
Age | 226 | 0.98 (0.96–1.01) | 0.189 |
History of diabetes |  | 1.33 (0.75–2.33) | 0.327 |
 Yes | 44 |  |  |
 No | 183 |  |  |
 Not sure | 2 |  |  |
TNM stage* |  | 1.2 (1–1.45) | 0.046 |
 IA | 28 |  |  |
 IB | 77 |  |  |
 IIA | 16 |  |  |
 IIB | 89 |  |  |
 III | 19 |  |  |
ECM subtype |  | 1.33 (0.97–1.82) | 0.076 |
 Deserted | 48 |  |  |
 Inter | 77 |  |  |
 Reactive | 85 |  |  |
Proteomic subtype* |  | 1.5 (1.09–2.06) | 0.012 |
 S-I | 57 |  |  |
 S-II | 106 |  |  |
 S-III | 54 |  |  |
Immune subtype** |  | 0.38 (0.2–0.7) | 0.002 |
 Im-S-I | 9 |  |  |
 Im-S-II | 15 |  |  |
 Im-S-III | 9 |  |  |
 Im-S-IV | 8 |  |  |
 Im-S-V | 13 |  |  |